65,437 trials
Infant, Newborn · Infant, Low Birth Weight · Infant, Small for Gestational Age
Primary: Population Pharmacokinetics: V - Volume — 0.6572 l/kg
Acute Pain · Pain
Primary: Change in Level of Pain Control as Reported on the NRS-11 — 9.38; 9.44; 7.51; 8.10 Units on a scale (1-10)
Breast Cancer Prevention
Primary: Change in Breast Density at 6 Months — -5.45; -13.71 cm^3
Head and Neck Cancer
Primary: Number of Participants With Treatment-Related Grade 3 or 4 Adverse Events as Assessed by CTCAE V4.0 — 2 Participants
Posttraumatic Stress Disorder
Primary: The Primary Outcome for This Study is Mean Change in Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) Over the Treatment Period of 10 Weeks Between the Losartan Arm…
Chronic Kidney Diseases · Iron Deficiency Anemia
Primary: Change From Baseline in Hemoglobin (Hgb) at Week 24 — 0.73; 0.70 grams per deciliter (g/dL)
Essential Tremor
Primary: Change in Tremor Rating Scale (TRS) Compared With Baseline. — 2.4; -0.2; 6.7; 3.6 units on a scale
Irritable Bowel Syndrome With Diarrhea (IBS-D)
Primary: Change From Baseline in Abdominal Pain at Its Worst on a NRS Through the Treatment Period — -2.01; -1.93; -1.58; -1.95 units on a scale — p=0.7467
Sleep Disordered Breathing
Primary: User Preference of the New Philips Respironics Positive Airway Pressure Application as Measured by the Attitudes Toward Use Questionnaire — 7.5; 7.9; 8.8 units on a scale
Tobacco Use Disorder · Medication Adherence
Primary: Varenicline Adherence as Measured by Pill Count — 61.8; 78.5 percentage pills taken/pills dispensed
Pancreatic Islet Transplantation in Type 1 Diabetes Mellitus
Primary: The Percentage of Insulin-independent Patients Following Single Infusion Islet Cell Transplantation at Day 75 +/- 5 — 0; 0 percentage of patients
Lung Lesion(s) Requiring Evaluation
Primary: Incidence of Pneumothorax (Grade 2+) — 44 Participants
Parkinson's Disease
Primary: Change From Baseline in the Percentage of "On" Time Without Dyskinesia Averaged Over Days 1 and 2 in Participants Treated With SUN N4057 and Those Treated With a Placebo…
Adult Solid Tumor · Adenocarcinoma of the Colon · Adenocarcinoma of the Rectum
Primary: Response Rates — 4; 0; 0; 0 Participants
HIV
Primary: Safety and Tolerability of Ibalizumab + OBR — 8; 9 participants